RT Journal Article
SR Electronic
T1 The association of pregnancy with disease progression in patients previously treated for differentiated thyroid cancer: A propensity score-matched retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.15.23287341
DO 10.1101/2023.03.15.23287341
A1 Li, Xin
A1 Xiao, Wu-Cai
A1 Mei, Fang
A1 Shan, Rui
A1 Song, Shi-Bing
A1 Sun, Bang-Kai
A1 Bao, He-Ling
A1 Chen, Jing
A1 Yuan, Chun-Hui
A1 Liu, Zheng
YR 2023
UL http://medrxiv.org/content/early/2023/03/16/2023.03.15.23287341.abstract
AB IMPORTANCE Differentiated thyroid cancer (DTC) is increasingly common in women of reproductive age. However, whether pregnancy increases the risk of progression/recurrence of DTC after treatment remains controversial due to the effect of confounding.OBJECTIVE To assess the effect of pregnancy on structural or biochemical progression in patients previously treated for DTC in a retrospective cohort using propensity score matching (PSM).DESIGN, SETTING, AND PARTICIPANTS This cohort study included 123 pregnant women and 1,376 non-pregnant women after initial treatment for DTC at Peking University Third Hospital between January 2012 and December 2022. To control the effect of confounding, we carefully matched pregnancy (n = 102) and non-pregnancy groups (n = 297) in terms of age, Hashimoto’s thyroiditis, lymph node dissection, extra-thyroid invasion, initial risk of recurrence after treatment, and time interval between treatment and last follow up by using PSM.EXPOSURES DTC patients became pregnant after previous treatment.MAIN OUTCOMES AND MEASURES The risk of structural or biochemical progression was assessed in the pregnancy and PSM matched non-pregnancy groups, respectively.Conditional logistics regression models were used to control important confounders and consider the matching properties of the data.RESULTS At baseline, the pregnancy (n = 102) and non-pregnancy groups (n = 297) were balanced in all matched variables (standardized differences <10% and P > 0.05). After a mean follow-up of approximately 4.5 years, we observed no evidence of difference between the two groups in growth in the size of existing metastatic foci [2 (2.0 %) vs. 2 (0.7 %); P = 0.346], percentage of patients developing new lymph node metastases [4 (3.9 %) vs. 21 (7.1 %); P = 0.519], node growth in the contralateral thyroid lobe [4 (3.9 %) vs. 16 (5.4 %); P = 0.324 ], or biochemical progression [2 (2.0 %) vs. 9 (3.0 %); P = 0.583]. Results from conditional logistic regressions and several sensitivity analyses also showed no evidence of association of pregnancy with the risk of progression, after adjusting for potential confounders of age, tumor size, initial risk stratification, Hashimoto’s thyroiditis, lymph node dissection, the time interval between treatment and follow-up, and achievement of TSH inhibition target (P = 0.354). The pregnancy-progression association observed longer than 4.5 years showed no evidence of difference with that observed shorter than 4.5 years (P for interaction was 0.283). We further classified the pregnancy patients into 3 subgroups based on the time interval between treatment and pregnancy (< 1 year, 1-2 years, ≥ 2 years) and found that the shorter the time interval, the higher the risk of DTC progression (P for trend was 0.043).CONCLUSIONS AND RELEVANCE The risk of DTC progression/recurrence in the pregnant women was not higher than that in the well-matched, non-pregnant women. For young women previously treated for DTC, disease progression might not be a concern for their future pregnancy plan, but it seems safer to wait an appropriate amount of time before pregnancy.Question Does pregnancy increase the risk of disease progression/recurrence in patients previously treated for differentiated thyroid cancer (DTC)?Findings This propensity score-matched retrospective cohort study included 399 patients previously treated for DTC. In a mean follow-up of approximately 4.5 years, the risk of progression in the pregnant group was not higher than the well-matched, non-pregnancy group, but the shorter time interval between treatment and pregnancy (≤ 2 years) appeared to increase the risk of disease progression.Meaning For young women previously treated for DTC, disease progression might not be a concern for their future pregnancy plan, but it seems safer to wait an appropriate amount of time before pregnancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the National Natural Science Foundation of China (81903433; 81672862) and the Fundamental Research Funds for the Central Universities (BMU2021YJ030).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical Research Ethics Committee of Peking University Third Hospital (No. IRB00006761-M2022721).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.